NCT00862524View on ClinicalTrials.gov

A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Advanced CancerPancreatic Cancer
Interventions
DRUG

ARRY-334543, EGFR/ErbB2 inhibitor; oral

multiple dose, escalating

DRUG

Gemcitabine, nucleoside analogue; intravenous

multiple dose, single schedule

Trial Locations (6)

37203

Sarah Cannon Research Center, Nashville

80045

University of Colorado Health Sciences Center, Aurora

85258

Pinnacle Oncology/Hematology, Phoenix

90404-2111

Premiere Oncology, Santa Monica

02114

Partners, Massachusetts General Hospital, Boston

02115

Partners, Dana Farber, Boston

Sponsors

Lead Sponsor

Array BioPharma
All Listed Sponsors
lead

Array BioPharma

INDUSTRY

NCT00862524 - A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer | Biotech Hunter | Biotech Hunter